Dr. Oz to pay for wearables that can help improve health

CMS, led by administrator Dr. Mehmet Oz, launched a voluntary 10-year pilot called Advancing Chronic Care with Effective, Scalable Solutions (ACCESS) to reimburse telehealth software, wearable devices and coaching apps for conditions including high blood pressure, diabetes, chronic musculoskeletal pain and depression. Qualified organizations will receive upfront payments tied to patient condition mix and only obtain full payment if they meet outcome-based targets; primary care clinicians can receive co-management fees and CMS will publish a performance directory. The program begins July 1, 2026, with applications in January, creating a potential reimbursement pathway that could expand addressable markets and revenue opportunities for digital health vendors and care organizations.

Analysis

Market structure: ACCESS materially increases demand for validated remote monitoring, coaching apps and wearables in Medicare's chronic-care cohort (≈65+M beneficiaries). Winners will be large-scale device/data incumbents (AAPL, GOOGL/GOOG, DXCM) and integrated care managers (UNH, CVS) that can credibly deliver risk-adjusted outcomes; niche one-off app vendors without scale risk commoditization. Pricing power shifts to platform owners who control data flows and provider integrations; expect margin expansion of 200–500bps for winners over 3–5 years if they capture national contracts.

Risk assessment: Tail risks include CMS policy reversal, fraud/overfitting of outcome metrics, or large privacy fines that delay adoption; assign a 10–15% probability to materially adverse regulatory action over 2 years. Short-term (days–months) volatility will track headlines and application timing (Jan 2026); medium-term (12–24 months) risk centers on first reported outcome cohorts; long-term (3–7 years) depends on demonstrated cost savings and scaling. Hidden dependencies: EHR integration, clinician referral economics, and patient adherence — failures here can negate reimbursement advantages.

Trade implications: Favor large-cap wearables and chronic-care telehealth leaders: AAPL, DXCM, TDOC, and payors UNH/CVS as portfolio overweight ideas to initiate before Jan 2026; avoid/underweight small-cap digital-health players without proven outcomes (e.g., AMWL). Use concentrated option structures to express convexity: buy 12–24 month call spreads on AAPL and TDOC to limit capital and capture upside if CMS adoption accelerates post-July 2026. Rebalance after the first ACCESS cohort outcomes are published (~12–18 months after start).

Contrarian angles: The market may overpay for early-stage digital therapeutics expecting rapid Medicare scale; historical parallel: Medicare DPP showed reimbursement ≠ scale. Expect cherry-picking and gaming of metrics initially — that could depress small-cap valuations when audits begin. Contrarian opportunity: buy quality integrated operators (UNH) on pullbacks >8% tied to implementation headlines, as they monetize co-management fees and reduce downstream cost exposure.

Key Decisions for Investors

• Establish a 2–3% long position in AAPL (buy) and hedge with a Jan 2027 1–2 year call spread to capture increased Medicare wearables demand; target +20–35% upside within 12–24 months, stop-loss -15%.
• Initiate a 2% long position in TDOC (Teladoc) via 12–18 month LEAPS calls or call spread to play chronic-care platforms that can demonstrate outcomes; target +30% in 12 months, stop -20% if CMS guidance tightens.
• Add a 2% overweight in UNH (UnitedHealth) or 2% in CVS (CVS) to capture co-management fees and reduced downstream costs; take profits if shares rise >15% or if ACCESS shows no-cost-savings after first cohort (12–18 months).
• Short 1–2% of AMWL (Amwell) or small-cap pure-play digital-health names lacking payer contracts; use equity short with a tight stop (10–15%) and consider buying 6–12 month puts if public disclosures fail to show ACCESS readiness by Jan 2026.
• Before positioning, monitor two catalysts: the Jan 2026 application rules (if requirements tighten materially, reduce exposure) and the first ACCESS outcome reports ~12–18 months after July 1, 2026 (if outcomes miss by >10% vs benchmarks, trim long positions).